MERRIMACK PHARMACEUTICALS INC
merrimack.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 15, 2024. Its latest SEC filing is a 15-12G from May 20, 2024.
10-Q for Q1 FY2024, filed May 15, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Receives milestone payments tied to cancer-drug rights sold to Ipsen and Elevation, and seeks buyers for remaining preclinical and clinical assets.
10-K for FY2023, filed Mar 7, 2024We are a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent…View ↗
On April 3, 2017, we completed the sale of ONIVYDE and MM-436 (the “commercial business”) to Ipsen (the “Ipsen sale”). In connection with…View ↗
On July 12, 2019, we completed the sale to Elevation, or the Elevation sale, of our anti-HER3 antibody programs, MM-121 (seribantumab) and…View ↗
Who Were Their Customers?
Ipsen bought the ONIVYDE and MM-436 commercial business, while Elevation bought the MM-121 and MM-111 programs; Merrimack is seeking buyers for its remaining preclinical and clinical assets.
10-K for FY2023, filed Mar 7, 2024We are a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent…View ↗
On April 3, 2017, we completed the sale of ONIVYDE and MM-436 (the “commercial business”) to Ipsen (the “Ipsen sale”). In connection with…View ↗
On July 12, 2019, we completed the sale to Elevation, or the Elevation sale, of our anti-HER3 antibody programs, MM-121 (seribantumab) and…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2024, filed May 15, 2024
$201.4MView ↗
- ▲ Now profitable
- vs −$271K in Q1 FY2023
-
May 10, 2024
Shareholders approve dissolution plan; company declares liquidating dividend
The dividend is expected around May 17, with delisting on May 20; further distributions could follow if reserves are released or milestones are achieved.
Sources
8-K, filed May 10, 2024
In connection with stockholder approval of the Plan of Dissolution obtained at the Special Meeting, on May 10, 2024, the Company issued a…View ↗
First-line ONIVYDE milestone
The first-line ONIVYDE milestone has moved from a potential payment to one Merrimack says it is entitled to receive following FDA approval.
10-K for FY2020, filed Mar 10, 2021 10-K for FY2023, filed Mar 7, 2024$225.0 million upon approval by the U.S. Food and Drug Administration, or FDA, of ONIVYDE for the first-line treatment of metastatic…View ↗
On February 13, 2024, we announced that Ipsen S.A. announced it had received approval from the U.S. Food and Drug Administration, or FDA…View ↗
Loading...
